Saturday, July 15, 2017 4:41:42 AM
Novartis CAR-T programmes
Candidate Target antigen *Indication Development
CTL019 CD19 B-ALL Pivotal phase II (ELIANA trial)
CTL019 CD19 DLBCL Pivotal phase II (JULIET trial)
BCMA MM Phase I/II
CTL119 CD19 CLL Human pilot
“CART22� CD22 B-ALL Terminated in phase I (June 2017)
Multiple Pre-clinical/phase I
HTTPS://clinicaltrials.gov/ct2/show/NCT02546167
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM